Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I-II cervical squamous cell carcinoma

Zhu,Weipei; Pan,Xiaohong; Yang,Zhujuan; Xing,Pengfei; Zhang,Yongshen; Li,Feng; Lu,Xueguan

doi:10.3892/ol.2015.3052

Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I-II cervical squamous cell carcinoma

Authors:
- Weipei Zhu
- Xiaohong Pan
- Zhujuan Yang
- Pengfei Xing
- Yongshen Zhang
- Feng Li
- Xueguan Lu
View Affiliations

Affiliations: Department of Gynecology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/ol.2015.3052
Pages: 2090-2094
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to investigate the expression of TAp73 and ΔNp73 in cervical squamous cancer cells, and to evaluate the prognostic significance of TAp73 and ΔNp73 expression in patients with International Federation of Gynecology and Obstetrics (FIGO) stage I‑II cervical squamous cell carcinoma (SCC). The immunohistochemical expression of TAp73 and ΔNp73 was evaluated in 59 FIGO stage I‑II cervical SCC tumor samples. Correlations with clinicopathological characteristics were determined by χ2 test. The prognostic impact of TAp73 and ΔNp73 expression with regard to overall survival (OS) was determined by the Kaplan‑Meier method. High TAp73 and ΔNp73 expression was detected in 79.7% (47/59) and 76.3% (45/59) of patients, respectively. The expression of TAp73 and ΔNp73 was not associated with age, FIGO stage, pathological differentiation or lymph node metastasis. The 3‑year OS rates associated with low and high TAp73 expression were 75.0 and 83.0%, respectively (χ2=0.33; P=0.568), whereas those associated with low and high ΔNp73 expression were 100.0 and 75.6%, respectively (χ2=3.90; P=0.048). High expression levels of TAp73 and ΔNp73 were frequently observed in the cervical squamous cancer cells. Overall, high expression levels of ΔNp73 may indicate an unfavorable prognosis in patients with early‑stage cervical SCC.

View Figures

View References

1	Lee MY and Shen MR: Epithelial-mesenchymal transition in cervical carcinoma. Am J Transl Res. 4:1–13. 2012.PubMed/NCBI
2	Sun Y, Liu JH, Jin L, et al: Over-expression of the Beclin1 gene upregulates chemosensitivity to anti-cancer drugs by enhancing therapy-induced apoptosis in cervix squamous carcinoma CaSki cells. Cancer Lett. 294:204–210. 2010. View Article : Google Scholar : PubMed/NCBI
3	Landoni F, Maneo A, Colombo A, et al: Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 350:535–540. 1997. View Article : Google Scholar : PubMed/NCBI
4	Komaki R, Brickner TJ, Hanlon AL, Owen JB and Hanks GE: Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978 and 1983: Patterns of Care Study (PCS). Int J Radiat Oncol Biol Phys. 31:973–982. 1995. View Article : Google Scholar : PubMed/NCBI
5	Biewenga P, van der Velden J, Mol BW, et al: Prognostic model for survival in patients with early stage cervical cancer. Cancer. 117:768–776. 2011. View Article : Google Scholar : PubMed/NCBI
6	Biewenga P, van der Velden J, Mol BW, et al: Validation of existing prognostic models in patients with early-stage cervical cancer. Gynecol Oncol. 115:277–284. 2009. View Article : Google Scholar : PubMed/NCBI
7	Bourdon JC: p53 family isoforms. Curr Pharm Biotechnol. 8:332–336. 2007. View Article : Google Scholar : PubMed/NCBI
8	Salomoni P and Dyer MJS: Delta N-p73: the enemy within. Cell Death Differ. 12:1553–1554. 2005. View Article : Google Scholar : PubMed/NCBI
9	Uramoto H, Sugio K, Oyama T, et al: Expression of the p53 family in lung cancer. Anticancer Res. 26:1785–1790. 2006.PubMed/NCBI
10	Khoury MP and Bourdon JC: p53 isoforms: an intracellular microprocessor? Genes Cancer. 2:453–465. 2011. View Article : Google Scholar : PubMed/NCBI
11	Müller M, Schilling T, Sayan AE, et al: TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12:1564–1577. 2005. View Article : Google Scholar : PubMed/NCBI
12	Domínguez G, García JM, Peña C, et al: Delta TAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 24:805–815. 2006. View Article : Google Scholar : PubMed/NCBI
13	Moll UM: The role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Clin Cancer Res. 9:5437–5441. 2003.PubMed/NCBI
14	Becker K, Pancoska P, Concin N, et al: Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol. 29:889–902. 2006.PubMed/NCBI
15	Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW and Ngan HY: Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res. 12:3922–3927. 2006. View Article : Google Scholar : PubMed/NCBI
16	Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Chloropoulou P, Liberis V and Sivridis E: High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol Oncol. 123:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
17	Grob TJ, Fey MF and Tobler A: The two faces of p73. Cell Death Differ. 9:229–230. 2002. View Article : Google Scholar : PubMed/NCBI
18	Soldevilla B, Millàn CS, Bonilla F and Domínguez G: The TP73 complex network: ready for clinical translation in cancer? Genes Chromosomes Cancer. 52:989–1006. 2013. View Article : Google Scholar : PubMed/NCBI
19	Melino G, Laurenzi V and Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2:605–615. 2002. View Article : Google Scholar : PubMed/NCBI
20	Hofstetter G, Berger A, Chamson M, et al: Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature. Int J Gynecol Pathol. 30:527–531. 2011. View Article : Google Scholar : PubMed/NCBI
21	Castellino RC, De Bortoli M, Lin LL, et al: Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer. 7:1272007. View Article : Google Scholar : PubMed/NCBI